Launch week offerEnds in00h00m00s

annual Promonthly Pro

Julia Frede

Professor

Technical University of Munich

Germany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Articles (11)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (5)

Katayoun Rezvani

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Martina Muckenthaler

Prof. Dr. phil. nat

University Medical Center

GERMANY

View details

Natalie Frede

University Medical Center Freiburg

GERMANY

View details

Yana Pikman

Boston Children's Hospital

UNITED STATES

View details

Fay Nicolson

Member of the Faculty

Dana-Farber Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Julia Frede

Research Interests

Make your next move.

Explore related searches

Articles (11)

Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy.

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis

Altered immune and treatment response gene expression signatures among povertyexposed children with B-cell acute lymphoblastic leukemia

Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia.

The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma

Cell-free DNA as a complementary marker of therapeutic futility in adenoid cystic carcinoma

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma

The 2024 generation.

B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation

Dual role of signaling pathways in myeloma requires cell type–specific targeting of ligand-receptor interactions

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering

Collaborators (5)

Katayoun Rezvani

Martina Muckenthaler

Natalie Frede

Yana Pikman

Fay Nicolson

Make your next move.